An Early Phase 1 interventional study of dihydroartemisinin in Acne Vulgaris, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Shanghai Zhongshan Hospital · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.
Among the 35 studies in Acne Vulgaris with a site in China, this one is the 21st largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 4 in phase 1, and was the 28th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:
Shenzhen People's Hospital · Sites in China
Ages 18–33
Shenyang Medical College · Sites in China
Ages 18–40
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Xiyuan Hospital of China Academy of Chinese Medical Sciences · Sites in China
Ages 18–50
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 14–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Median enrollment 100 across the 33 interventional studies, 190 across the 2 observational. Of the 18 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 35 have an industry lead sponsor. The 10 most frequent:
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Shanghai Zhongshan Hospital has 1 study filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
2 of the studies in Acne Vulgaris with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
| NCT06763367Nanjing First Hospital, Nanjing Medical UniversityClinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis | 2026-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Acne Vulgaris with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: dihydroartemisinin
DHA 40mg tid for 90 days
Improvement of acne severity by Investigator's Global Assessment (IGA)
Improvement of acne severity is considered clinically significant if a subject's IGA improves by at least one grade
Time frame: Before and immediately after 90-day treatment
Change of Global Acne Grading System (GAGS) score from baseline to the end of treatment
An improvement of ≥30% in the GAGS score will be considered significant
Time frame: Before and immediately after 90-day treatment
Change of inflammatory lesion count from baseline to the end of treatment
Time frame: Before and immediately after 90-day treatment
Change of non-inflammatory lesion count from baseline to the end of treatment
Time frame: Before and immediately after 90-day treatment
Number of participants who achieved an IGA score of 0 or 1 at the end of treatment
Time frame: Before and immediately after 90-day treatment
Change of serum total testosterone from baseline to the end of treatment
Time frame: Before and immediately after 90-day treatment
Plan to share: Yes — All IPD that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication
Access criteria: IPD and supporting information will be avaible to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for May 2026, 11 months later.
Of 51 phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 11 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Artenimol